NCT03500562 is a clinical trial in Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03500562?

NCT03500562 is sponsored by Bristol-Myers Squibb.

What condition does NCT03500562 study?

NCT03500562 studies Chronic Hepatitis C.

Is NCT03500562 still recruiting?

NCT03500562 is currently terminated. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT03500562

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Terminated Last updated 1 September 2021

What this trial tests

trial in Chronic Hepatitis C in 3 participants. Terminated before completion.

Timeline

8 May 2018

Primary endpoint
29 March 2019

29 March 2019

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	8 May 2018
Primary completion	29 March 2019
Estimated completion	29 March 2019
Sites	2 locations across China

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Chronic Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03500562 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03500562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing